1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 70, 2019
  5. Article

Annual Review of Medicine

Volume 70, 2019

Non–Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation

Abstract

Atrial fibrillation (AF) increases a patient's stroke risk four- to five-fold. Anticoagulation with the vitamin K antagonist (VKA) warfarin reduces the risk of stroke by 67%, but warfarin carries a significant risk of major bleeding and has unpredictable pharmacodynamics with a narrow therapeutic window, necessitating frequent monitoring of its anticoagulant effect. The non–vitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban provide more predictable anticoagulant activity than warfarin with a lower risk of major bleeding, and each is noninferior to warfarin for the prevention of stroke. All have earned regulatory approval in the past eight years. At least one of the NOACs is approved for use in all patients with AF, except those with mechanical valves and rheumatic mitral valve disease, for whom warfarin remains the only option. Recent clinical trials have shown that antithrombotic regimens including NOACs are safe and effective in patients with AF who need potent antiplatelet therapy.

Keyword(s): atrial fibrillation, non–vitamin K antagonist oral anticoagulants, stroke prevention
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042617-092334
2019-01-27
2024-04-16
Loading full text...

Full text loading...

/deliver/fulltext/med/70/1/annurev-med-042617-092334.html?itemId=/content/journals/10.1146/annurev-med-042617-092334&mimeType=html&fmt=ahah

Literature Cited

  1. 1.  Benjamin EJ, Blaha MJ, Chiuve SE et al. 2017. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation 135:10e146–e603
     [Google Scholar]
  2. 2.  Rahman F, Kwan GF, Benjamin EJ 2014. Global epidemiology of atrial fibrillation. Nat. Rev. Cardiol. 11:11639–54
     [Google Scholar]
  3. 3.  Chugh SS, Havmoeller R, Narayanan K et al. 2014. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129:8837–47
     [Google Scholar]
  4. 4.  Kamel H, Okin PM, Elkind MS, Iadecola C 2016. Atrial fibrillation and mechanisms of stroke. Stroke 47:3895–900
     [Google Scholar]
  5. 5.  Wolf PA, Abbott RD, Kannel WB 1991. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:8983–88
     [Google Scholar]
  6. 6.  Gage BF, Waterman AD, Shannon W et al. 2001. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:222864–70
     [Google Scholar]
  7. 7.  Hart RG, Pearce LA, Aguilar MI 2007. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146:12857–67
     [Google Scholar]
  8. 8.  van Walraven C, Hart RG, Singer DE et al. 2002. Oral anticoagulants versus aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 288:192441–48
     [Google Scholar]
  9. 9.  Kirchhof P, Benussi S, Kotecha D et al. 2016. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 37:382893–962
     [Google Scholar]
  10. 10.  January CT, Wann LS, Alpert JS et al. 2014. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 64:21e1–76 Corrigendum 2014. J. Am. Coll. Cardiol. 64:212305–7 https://doi.org/10.1016/j.jacc.2014.04.005
    [Crossref] [Google Scholar]
  11. 11.  Chen JY, Zhang AD, Lu HY et al. 2013. CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. J. Geriatr. Cardiol. 10:3258–66
     [Google Scholar]
  12. 12.  Rasmussen MA, Skov J, Bladbjerg E-M et al. 2012. Multivariate analysis of the relation between diet and warfarin dose. Eur. J. Clin. Pharmacol. 68:3321–28
     [Google Scholar]
  13. 13.  Garcia D, Regan S, Crowther M et al. 2005. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 127:62049–56
     [Google Scholar]
  14. 14.  Baker WL, Cios DA, Sander SD, Coleman CI 2009. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J. Manag. Care Pharm. 15:3244–52
     [Google Scholar]
  15. 15.  Mauri L, D'Agostino Sr.RB 2017. Challenges in the design and interpretation of noninferiority trials. N. Engl. J. Med. 377:141357–67
     [Google Scholar]
  16. 16.  Connolly SJ, Ezekowitz MD, Yusuf S et al. 2009. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361:121139–51
     [Google Scholar]
  17. 17. ROCKET AF Study Investigators 2010. Rivaroxaban—once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am. Heart J. 159:3340–47.e1
     [Google Scholar]
  18. 18.  Patel MR, Mahaffey KW, Garg J et al. 2011. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365:10883–91
     [Google Scholar]
  19. 19.  Granger CB, Alexander JH, McMurray JJ et al. 2011. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365:11981–92
     [Google Scholar]
  20. 20.  Giugliano RP, Ruff CT, Braunwald E et al. 2013. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369:222093–104
     [Google Scholar]
  21. 21.  Ruff CT, Giugliano RP, Braunwald E et al. 2014. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:9921955–62
     [Google Scholar]
  22. 22.  Lee S, Monz BU, Clemens A et al. 2012. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. BMJ Open 2:6e001768
     [Google Scholar]
  23. 23.  Chan KE, Giugliano RP, Patel MR et al. 2016. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J. Am. Coll. Cardiol. 67:242888–99
     [Google Scholar]
  24. 24.  Camm AJ, Amarenco P, Haas S et al. 2014. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vasc. Health Risk Manag. 10:425
     [Google Scholar]
  25. 25.  Camm AJ, Amarenco P, Haas S et al. 2015. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur. Heart J. 37:141145–53
     [Google Scholar]
  26. 26.  Larsen TB, Skjøth F, Nielsen PB et al. 2016. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189
     [Google Scholar]
  27. 27.  Yao X, Abraham NS, Sangaralingham LR et al. 2016. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J. Am. Heart Assoc. 5:6e003725
     [Google Scholar]
  28. 28.  Maura G, Blotière P-O, Bouillon K et al. 2015. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation 132:131252–60
     [Google Scholar]
  29. 29.  Lip GY, Keshishian A, Kamble S et al. 2016. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thromb. Haemost. 116:5975–86
     [Google Scholar]
  30. 30.  Villines TC, Schnee J, Fraeman K et al. 2015. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb. Haemost. 114:061290–98
     [Google Scholar]
  31. 31.  Adeboyeje G, Sylwestrzak G, Barron JJ et al. 2017. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. J. Manag. Care Spec. Pharm. 23:9968–78
     [Google Scholar]
  32. 32.  Graham DJ, Reichman ME, Wernecke M et al. 2015. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation 131:2157–64
     [Google Scholar]
  33. 33.  Deitelzweig S, Farmer C, Luo X et al. 2017. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. Curr. Med. Res. Opin. 33:91583–94
     [Google Scholar]
  34. 34.  Steinberg BA, Shrader P, Thomas L et al. 2016. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. J. Am. Coll. Cardiol. 68:242597–604
     [Google Scholar]
  35. 35.  Hsu JC, Maddox TM, Kennedy K et al. 2016. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J. Am. Coll. Cardiol. 67:252913–23
     [Google Scholar]
  36. 36.  Warkentin AE, Donadini MP, Spencer FA et al. 2012. Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta‐analysis. J. Thromb. Haemost. 10:4512–20
     [Google Scholar]
  37. 37.  Connolly SJ, Eikelboom J, Joyner C et al. 2011. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364:9806–17
     [Google Scholar]
  38. 38.  Lamberts M, Gislason GH, Lip GYH et al. 2014. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 129:151577–85
     [Google Scholar]
  39. 39.  Eikelboom JW, Connolly SJ, Brueckmann M et al. 2013. Dabigatran versus warfarin in patients with mechanical heart valves. N. Engl. J. Med. 369:131206–14
     [Google Scholar]
  40. 40.  Avezum A, Lopes RD, Schulte PJ et al. 2015. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease. Circulation 132:8624–32
     [Google Scholar]
  41. 41.  Ezekowitz MD, Nagarakanti R, Noack H et al. 2016. Comparison of dabigatran versus warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial. Circulation 134:589–98
     [Google Scholar]
  42. 42.  Breithardt G, Baumgartner H, Berkowitz SD et al. 2014. Clinical characteristics and outcomes with rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur. Heart J. 35:473377–85
     [Google Scholar]
  43. 43.  De Caterina R, Renda G, Carnicelli AP et al. 2017. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J. Am. Coll. Cardiol. 69:111372–82
     [Google Scholar]
  44. 44.  Pan KL, Singer DE, Ovbiagele B et al. 2017. Effects of non–vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta‐analysis. J. Am. Heart Assoc. 6:7e005835
     [Google Scholar]
  45. 45.  Canestaro WJ, Patrick AR, Avorn J et al. 2013. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes 6:6724–31
     [Google Scholar]
  46. 46.  Baumann Kreuziger LM, Keenan JC, Morton CT, Dries DJ 2014. Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates. Biomed. Res. Int. 2014:583794
     [Google Scholar]
  47. 47.  Enriquez A, Lip GY, Baranchuk A 2015. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace 18:7955–64
     [Google Scholar]
  48. 48.  Pollack CV Jr., Reilly PA, Eikelboom J et al. 2015. Idarucizumab for dabigatran reversal. N. Engl. J. Med. 373:6511–20
     [Google Scholar]
  49. 49.  Sterne JA, Bodalia PN, Bryden PA et al. 2017. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol. Assess. Rep. 21:91–386
     [Google Scholar]
  50. 50.  Morimoto T, Crawford B, Wada K, Ueda S 2015. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: a network meta-analysis with the adjustment for the possible bias from open label studies. J. Cardiol. 66:6466–74
     [Google Scholar]
  51. 51.  Tereshchenko LG, Henrikson CA, Cigarroa J, Steinberg JS 2016. Comparative effectiveness of interventions for stroke prevention in atrial fibrillation: a network meta‐analysis. J. Am. Heart Assoc. 5:5e003206
     [Google Scholar]
  52. 52.  Camm AJ, Fox KA, Peterson E 2017. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. Europace 20:11–11
     [Google Scholar]
  53. 53.  Noseworthy PA, Yao X, Abraham NS et al. 2016. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest 150:61302–12
     [Google Scholar]
  54. 54.  Graham DJ, Reichman ME, Wernecke M et al. 2016. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern. Med. 176:111662–71
     [Google Scholar]
  55. 55.  Fitzgerald JL, Howes LG 2016. Drug interactions of direct-acting oral anticoagulants. Drug Saf 39:9841–45
     [Google Scholar]
  56. 56.  Soliman EZ, Safford MM, Muntner P et al. 2014. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern. Med. 174:1107–14
     [Google Scholar]
  57. 57.  Fosbol EL, Wang TY, Li S et al. 2012. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non–ST elevation myocardial infarction. Am. Heart J. 163:4720–28
     [Google Scholar]
  58. 58.  Gibson CM, Mehran R, Bode C et al. 2016. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N. Engl. J. Med. 375:252423–34
     [Google Scholar]
/content/journals/10.1146/annurev-med-042617-092334
Loading
Non–Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation
Annual Review of Medicine 70, 61 (2019); https://doi.org/10.1146/annurev-med-042617-092334
/content/journals/10.1146/annurev-med-042617-092334
/content/journals/10.1146/annurev-med-042617-092334
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error